Filing Details
- Accession Number:
- 0000950170-24-061321
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-05-16 21:53:56
- Reporting Period:
- 2024-05-14
- Accepted Time:
- 2024-05-16 21:53:56
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1157601 | Madrigal Pharmaceuticals Inc. | MDGL | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1014095 | B Fred Craves | C/O Bay City Capital Llc, 1000 4Th Street, Suite 500 San Rafael CA 94901 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-05-14 | 10,000 | $100.45 | 423,362 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-05-14 | 12,489 | $105.08 | 435,851 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-05-14 | 8,827 | $210.99 | 427,024 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-05-14 | 5,009 | $211.84 | 422,015 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-05-14 | 1,363 | $212.85 | 420,652 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-05-14 | 2,190 | $213.85 | 418,462 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-05-14 | 1,804 | $214.68 | 416,658 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-05-14 | 375 | $216.08 | 416,283 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-05-14 | 721 | $216.98 | 415,562 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-05-14 | 1,100 | $217.86 | 414,462 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-05-14 | 1,000 | $218.99 | 413,462 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-05-14 | 100 | $219.90 | 413,362 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2024-05-14 | 10,000 | $0.00 | 10,000 | $100.45 |
| Common Stock | Stock Option (right to buy) | Disposition | 2024-05-14 | 12,489 | $0.00 | 12,489 | $105.08 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2024-06-27 | No | 4 | M | Direct | |
| 0 | 2024-06-17 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 1,261 | Indirect | See Footnotes |
| Common Stock | 57,062 | Indirect | See Footnotes |
| Common Stock | 18,000 | Indirect | See Footnotes |
Footnotes
- These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.34 to $211.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.34 to $212.33, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.36 to $213.31 inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.36 to $214.34 inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.39 to $215.27 inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.61 to $216.58 inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.61 to $217.23 inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.64 to $218.37 inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.68 to $219.34 inclusive.
- These securities are held by Bay City Capital LLC ("BCC"). Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.
- Represents shares held indirectly by Dr. Craves through a grantor retained annuity trust.
- Represents shares held indirectly by Dr. Craves through the Craves Family Foundation.
- The shares underlying this stock option are fully vested.
Billionaire Hedge Funds
